Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos. Gilead is acquiring Ouro Medicines for approximately $2.175 billion,…
Gilead to acquire immunology biotech, offers lifeline to Galapagos. Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease…
Gilead Sciences and Lakefront complete acquisition of Ouro Medicines to further expand inflammation pipeline. Lakefront is responsible for the ongoing and…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Gilead completed its acquisition of privately held Ouro Medicines on June 4, 2026 (announced March 23, 2026), paying $1.675B upfront plus up to $500M in contingent milestones (~$2.175B total) for BCMAxCD3 T-cell engager OM336/gamgertamig, in Phase 1/2 for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and carrying FDA Fast Track and Orphan Drug designations in both. Under a concurrent collaboration, Lakefront Biotherapeutics (the former Galapagos NV, which rebranded effective May 8, 2026) absorbed Ouro's R&D team and runs the ongoing Phase 1/2 studies; Gilead leads registrational and later-stage development and commercialization ex-Greater China. The two companies split the upfront and milestone payments equally, and Lakefront receives tiered 20-23% royalties on gamgertamig net sales. Registrational studies are expected to begin as early as 2027, extending Gilead's inflammation franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Ouro Medicines, Inc. (this deal) | 2026 | $2.2B | — |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2026 deals · Gilead Sciences Inc. deals · Hematology deals